☆ 4.5 Review

Novel systemic therapies in the management of tyrosine kinase inhibitor-pretreated patients with epidermal growth factor receptor-mutant non-small-cell lung cancer

THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2023)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Oncology

CD70 is a therapeutic target upregulated in EMT-associated EGFR tyrosine kinase inhibitor resistance

Monique B. Nilsson et al.

Summary: This study identified CD70 as a significantly upregulated cell surface protein in non-small cell lung cancer (NSCLC) patients with acquired resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) through epithelial-to-mesenchymal transition (EMT). CD70 promotes cell survival and invasiveness by reactivating signal transduction pathways associated with acquired TKI resistance. Anti-CD70 antibody drug conjugates (ADCs) as well as CD70-targeting chimeric antigen receptor (CAR) T cells and CAR NK cells showed strong activity against EGFR TKI-resistant cells. These findings suggest that CD70 could serve as a therapeutic target for EGFR mutant tumors with acquired TKI resistance.

CANCER CELL (2023)

添加到收藏夹

Article Oncology

Phase Ib Study of Telisotuzumab Vedotin in Combination With Erlotinib in Patients With c-Met Protein-Expressing Non-Small-Cell Lung Cancer

D. Ross Camidge et al.

Summary: This study evaluated the efficacy and safety of Teliso-V plus erlotinib in EGFR-M+ and c-Met+ NSCLC patients, and the results showed encouraging antitumor activity and acceptable toxicity in EGFR TKI-pretreated patients with EGFR-M+, c-Met+ NSCLC.

JOURNAL OF CLINICAL ONCOLOGY (2023)

添加到收藏夹

Article Oncology

Osimertinib plus Savolitinib to Overcome Acquired MET-Mediated Resistance in Epidermal Growth Factor Receptor-Mutated, MET-Amplified Non-Small Cell Lung Cancer: TATTON

Ryan J. Hartmaier et al.

Summary: Combining MET inhibitor and EGFR tyrosine kinase inhibitor can overcome acquired osimertinib resistance mediated by MET. In this study, savolitinib and osimertinib combination therapy showed promising results in advanced non-small cell lung cancer patients with MET amplification and EGFR mutation who had progressed on prior EGFR-TKI treatment. The combination therapy demonstrated acceptable safety profile and improved antitumor activity.

CANCER DISCOVERY (2023)

添加到收藏夹

Article Oncology

EGFR inhibition in EGFR-mutant lung cancer cells perturbs innate immune signaling pathways in the tumor microenvironment

Akihiko Shiiya et al.

Summary: EGFR-tyrosine kinase inhibitors induce changes in tumor phenotype and immune escape mechanisms in EGFR-mutant non-small-cell lung cancer cells. These inhibitors upregulate the expression of CD24, an innate immune checkpoint, in EGFR-mutant cells. In addition, EGFR inhibition accelerates the release of cell-free DNA from dying tumor cells, activating interferon signaling pathways. CD24 targeted therapy and cfDNA monitoring may improve treatment outcomes in patients with EGFR-mutant NSCLC.

CANCER SCIENCE (2023)

添加到收藏夹

Article Oncology

Rationale and value of consolidative cranial local therapy in EGFR-mutant non-small cell lung cancer patients with baseline brain metastasis treated with first-line EGFR-TKIs

Ya Zeng et al.

Summary: This study aims to explore the rationale and value of consolidative cranial local therapy (CLT) in patients with brain metastases (BMs) who have EGFR-mutant non-small cell lung cancer (NSCLC). The results of the study show that cranial progressive disease mainly occurs at the residual cranial lesions after EGFR-TKI treatment. Therefore, consolidative cranial local therapy targeting the oligo-residual cranial tumor lesions may provide survival benefit.

THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2023)

添加到收藏夹

Article Oncology

ESMO expert consensus statements on the management of EGFR mutant non-small-cell lung cancer

A. Passaro et al.

Summary: The European Society for Medical Oncology (ESMO) conducted a virtual consensus-building process in 2021 to discuss the management of EGFR-mutant non-small-cell lung cancer. The experts developed recommendations on various topics, including tissue and biomarkers analyses, early and locally advanced disease, metastatic disease, clinical trial design, patient's perspective, and miscellaneous.

ANNALS OF ONCOLOGY (2022)

添加到收藏夹

Article Oncology

A Randomized Phase II Study Comparing Nivolumab with Carboplatin-Pemetrexed for EGFR-Mutated NSCLC with Resistance to EGFR Tyrosine Kinase Inhibitors (WJOG8515L)

Hidetoshi Hayashi et al.

Summary: The study found that nivolumab did not show a longer progression-free survival (PFS) compared to carboplatin-pemetrexed in NSCLC patients with EGFR tyrosine kinase inhibitor resistance. However, gene expression profiling identified some tumors with a favorable immune microenvironment associated with the efficacy of nivolumab.

CLINICAL CANCER RESEARCH (2022)

添加到收藏夹

Article Oncology

A Novel Third-generation EGFR Tyrosine Kinase Inhibitor Abivertinib for EGFR T790M-mutant Non-Small Cell Lung for Cancer: a Multicenter Phase I/II Study

Qing Zhou et al.

Summary: Abivertinib at a dose of 300 mg twice a day demonstrated favorable clinical efficacy with manageable side effects in patients with EGFR T790M(+) NSCLC.

CLINICAL CANCER RESEARCH (2022)

添加到收藏夹

Article Oncology

INSIGHT 2: a Phase II study of tepotinib plus osimertinib in MET-amplified NSCLC and first-line osimertinib resistance

Egbert F. Smit et al.

Summary: Combining osimertinib with MET inhibitor like tepotinib could potentially overcome resistance driven by MET amplification in NSCLC patients, and the ongoing study INSIGHT 2 aims to evaluate the efficacy and safety of this combination therapy for patients with acquired resistance to osimertinib due to MET amplification.

FUTURE ONCOLOGY (2022)

添加到收藏夹

Article Oncology

A Phase 1/2 Study of Lazertinib 240 mg in Patients With Advanced EGFR T790M-Positive NSCLC After Previous EGFR Tyrosine Kinase Inhibitors

Byoung Chul Cho et al.

Summary: This study evaluated the efficacy and safety of lazertinib in patients with advanced T790M-positive NSCLC after previous EGFR TKI therapy. The results demonstrated that lazertinib has a manageable safety profile with durable antitumor efficacy in this patient population.

JOURNAL OF THORACIC ONCOLOGY (2022)

添加到收藏夹

Article Oncology

Single-cell transcriptome analysis revealed a suppressive tumor immune microenvironment in EGFR mutant lung adenocarcinoma

Lei Yang et al.

Summary: This study investigates the immune microenvironment of EGFR-mutant and EGFR wild-type lung adenocarcinomas (LUADs) using single-cell transcriptome sequencing and multiplex immunohistochemistry. The results show that EGFR-mutant LUAD lacks CD8(+) tissue-resident memory (TRM) cells and has less crosstalk between T cells and other cell types compared to EGFR wild-type LUAD. These findings contribute to a better understanding of the immune landscape of EGFR-mutant LUAD at the single-cell level and suggest that the lack of CD8(+) TRM cells may be a key factor in the suppressive TME of EGFR-mutant LUAD.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2022)

添加到收藏夹

Article Medicine, General & Internal

Subsequent treatments beyond progression on osimertinib in EGFR-mutated NSCLC and leptomeningeal metastases

Mei-Mei Zheng et al.

Summary: This study revealed site-specific resistant mechanisms to osimertinib and investigated subsequent treatments for leptomeningeal metastases (LM) in EGFR-mutated NSCLC patients. Private resistant mechanisms in cerebrospinal fluid (CSF) might match osimertinib-resistant LM for targeted therapy. Continuing osimertinib with intensification strategy might prolong survival, especially for those with CNS-only progression.

BMC MEDICINE (2022)

添加到收藏夹

Article Oncology

AENEAS: A Randomized Phase III Trial of Aumolertinib Versus Gefitinib as First-Line Therapy for Locally Advanced or Metastatic Non-Small-Cell Lung Cancer With EGFR Exon 19 Deletion or L858R Mutations

Shun Lu et al.

Summary: This study evaluated the efficacy and safety of Aumolertinib as a first-line treatment for locally advanced or metastatic EGFR-mutated non-small-cell lung cancer. The results showed that Aumolertinib had significantly longer progression-free survival compared to gefitinib, and the objective response rate and disease control rate were similar between the two drugs. Aumolertinib is a well-tolerated treatment option.

JOURNAL OF CLINICAL ONCOLOGY (2022)

添加到收藏夹

Article Medicine, General & Internal

Trastuzumab Deruxtecan in HER2-Mutant Non-Small-Cell Lung Cancer

Bob T. Li et al.

Summary: Trastuzumab deruxtecan demonstrated durable anticancer activity in previously treated HER2-mutant NSCLC patients, with two cases of fatal drug-related interstitial lung disease reported. The observed toxic effects were generally consistent with previous studies.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

添加到收藏夹

Article Oncology

Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor-Resistant, EGFR-Mutated Non-Small Cell Lung Cancer

Pasi A. Janne et al.

Summary: HER3-DXd shows clinical activity in EGFR TKI-resistant lung cancer, regardless of resistance mechanisms, providing a new approach to treat drug-resistant cancers.

CANCER DISCOVERY (2022)

添加到收藏夹

Article Critical Care Medicine

Bevacizumab plus erlotinib versus erlotinib alone in Japanese patients with advanced, metastatic, EGFR-mutant non-small-cell lung cancer (NEJ026): overall survival analysis of an open-label, randomised, multicentre, phase 3 trial

Yosuke Kawashima et al.

Summary: The combination treatment of bevacizumab and erlotinib did not prolong overall survival in patients with metastatic EGFR-mutant NSCLC, but both treatment groups showed relatively long survival durations.

LANCET RESPIRATORY MEDICINE (2022)

添加到收藏夹

Article Critical Care Medicine

Furmonertinib (AST2818) versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer (FURLONG): a multicentre, double-blind, randomised phase 3 study

Yuankai Shi et al.

LANCET RESPIRATORY MEDICINE (2022)

添加到收藏夹

Article Biochemistry & Molecular Biology

Overall survival with circulating tumor DNA-guided therapy in advanced non-small-cell lung cancer

Justin Jee et al.

Summary: This study followed a cohort of 1,127 patients with non-small-cell lung cancer and ctDNA-guided therapy, and found that ctDNA detection was associated with shorter survival, independent of clinicopathologic features and metabolic tumor volume. Additionally, targeted therapy guided by ctDNA sequencing was associated with longer survival. The study also identified genomic alterations in ctDNA that were not detected by tissue sequencing, highlighting the potential of ctDNA profiling to expand access to life-prolonging therapy.

NATURE MEDICINE (2022)

添加到收藏夹

Review Oncology

Refining patient selection of MET-activated non-small cell lung cancer through biomarker precision

Gillianne G. Y. Lai et al.

Summary: Dysregulated MET signaling plays an important role in lung oncogenesis. MET overexpression, gene amplification, or mutation can all lead to MET dysregulation. METex14 is a reliable predictor of response to selective MET tyrosine kinase inhibitors (TKIs), and MET amplification is associated with the response to MET-TKIs. Therefore, the detection methods for METex14, MET amplification, and MET overexpression are crucial, but there are challenges and evidence gaps in their clinical application.

CANCER TREATMENT REVIEWS (2022)

添加到收藏夹

Article Oncology

Aumolertinib activity in patients with CNS metastases and EGFR-mutated NSCLC treated in the randomized double-blind phase III trial (AENEAS).

Shun Lu et al.

JOURNAL OF CLINICAL ONCOLOGY (2022)

添加到收藏夹

Article Oncology

A phase 1/2 study of the highly selective EGFR inhibitor, BLU-701, in patients with EGFR-mutant non–small cell lung cancer (NSCLC).

Alexander I. Spira et al.

JOURNAL OF CLINICAL ONCOLOGY (2022)

添加到收藏夹

Article Oncology

Central nervous system efficacy of furmonertinib versus gefitinib in patients with non–small cell lung cancer with epidermal growth factor receptor mutations: Results from FURLONG study.

Gongyan Chen et al.

JOURNAL OF CLINICAL ONCOLOGY (2022)

添加到收藏夹

Article Oncology

Amivantamab and lazertinib in patients with EGFR-mutant non–small cell lung (NSCLC) after progression on osimertinib and platinum-based chemotherapy: Updated results from CHRYSALIS-2.

Catherine A. Shu et al.

JOURNAL OF CLINICAL ONCOLOGY (2022)

添加到收藏夹

Article Chemistry, Medicinal

Discovery of BLU-945, a Reversible, Potent, and Wild-Type-Sparing Next-Generation EGFR Mutant Inhibitor for Treatment-Resistant Non-Small-Cell Lung Cancer

Meredith S. Eno et al.

Summary: While EGFR tyrosine kinase inhibitors have revolutionized the treatment of NSCLC, the development of resistance mutations remains a challenge. This study introduces a novel reversible inhibitor, BLU-945, that shows promising activity against different resistance mutations. Clinical trials are currently underway to evaluate its efficacy and safety.

JOURNAL OF MEDICINAL CHEMISTRY (2022)

添加到收藏夹

Article Oncology

Sintilimab plus bevacizumab biosimilar IBI305 and chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): first interim results from a randomised, double-blind, multicentre, phase 3trial

Shun Lu et al.

Summary: The study evaluated the efficacy and safety of sintilimab with or without IBI305, combined with pemetrexed and cisplatin, for treating EGFR mutated non-small-cell lung cancer patients. The interim analysis showed prolonged progression-free survival in patients treated with sintilimab plus IBI305 plus chemotherapy compared to chemotherapy alone.

LANCET ONCOLOGY (2022)

添加到收藏夹

Meeting Abstract Oncology

Tepotinib plus osimertinib for EGFRm NSCLC with MET amplification (METamp) after progression on first-line (1L) osimertinib: Initial results from the INSIGHT 2 study

J. Mazieres et al.

ANNALS OF ONCOLOGY (2022)

添加到收藏夹

Article Oncology

Bioinformatically Expanded Next-Generation Sequencing Analysis Optimizes Identification of Therapeutically Relevant MET Copy Number Alterations in >50,000 Tumors

James P. Solomon et al.

Summary: This study validated and optimized the utility of next-generation sequencing (NGS) in assessing MET copy number alterations, achieving high concordance, sensitivity, and specificity. MET copy gains and amplifications were found in certain malignancies, with high-level/focal amplification associated with targeted therapy response.

CLINICAL CANCER RESEARCH (2022)

添加到收藏夹

Review Oncology

Asian Thoracic Oncology Research Group (ATORG) Expert Consensus Statement on MET Alterations in NSCLC: Diagnostic and Therapeutic Considerations

Myung-Ju Ahn et al.

Summary: Non-small cell lung cancer is a heterogeneous disease with various oncogenic driver mutations. Mutations in the MET gene are associated with tumorigenesis and drug resistance. There are differences in diagnosing MET alterations and using targeted therapies across countries in Asia-Pacific. The Asian Thoracic Oncology Research Group provides consensus recommendations for standardized approaches.

CLINICAL LUNG CANCER (2022)

添加到收藏夹

Article Oncology

EP08.02-140 MET Biomarker-based Preliminary Efficacy Analysis in SAVANNAH: savolitinib+osimertinib in EGFRm NSCLC Post-Osimertinib

M-j. Ahn et al.

Journal of Thoracic Oncology (2022)

添加到收藏夹

Article Oncology

MA07.09 BBT-176, a 4th generation EGFR TKI, for Progressed NSCLC after EGFR TKI Therapy: PK, Safety and Efficacy from Phase 1 Study

S.M. Lim et al.

Journal of Thoracic Oncology (2022)

添加到收藏夹

Article Oncology

MA07.04 Amivantamab and Lazertinib in Combination with Platinum-Based Chemotherapy in Relapsed/Refractory EGFR-mutant NSCLC

M.E. Marmarelis et al.

Journal of Thoracic Oncology (2022)

添加到收藏夹

Editorial Material Oncology

MET inhibitors for MET amplification-What's the most appropriate detection method and cut-off value?

Liwei Zhang et al.

LUNG CANCER (2022)

添加到收藏夹

Meeting Abstract Oncology

Nivolumab (NIVO) plus chemotherapy (chemo) vs chemo in patients (pts) with EGFR-mutated metastatic non-small cell lung cancer (mNSCLC) with disease progression after EGFR tyrosine kinase inhibitors (TKIs) in CheckMate 722

T. S. K. Mok et al.

ANNALS OF ONCOLOGY (2022)

添加到收藏夹

Meeting Abstract Oncology

A randomized, double-blind, multinational phase III study to assess the efficacy and safety of lazertinib versus gefitinib in the first-line treatment of patients with EGFR mutation (EGFRm), advanced NSCLC (LASER301; NCT04248829)

B. C. Cho et al.

ANNALS OF ONCOLOGY (2022)

添加到收藏夹

Article Oncology

A phase Ib study of the highly selective MET-TKI savolitinib plus gefitinib in patients withEGFR-mutated,MET-amplified advanced non-small-cell lung cancer

Jin-Ji Yang et al.

Summary: In this study, combination therapy of Savolitinib with gefitinib showed potential in terms of safety and efficacy for EGFRm, MET-amplified NSCLC patients, although further observation is needed to determine its specific efficacy.

INVESTIGATIONAL NEW DRUGS (2021)

添加到收藏夹

Article Oncology

P47.05 A Phase 2 Study of Datopotamab Deruxtecan (Dato-DXd) in Advanced NSCLC With Actionable Genomic Alterations (TROPION-Lung05)

M. Johnson et al.

Journal of Thoracic Oncology (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology

Discovery of amivantamab (JNJ-61186372), a bispecific antibody targeting EGFR and MET

Joost Neijssen et al.

Summary: This study focused on developing a bispecific antibody targeting EGFR and MET pathways to overcome resistance to targeted therapies in nonsmall cell lung cancer patients. By sequentially screening a panel of BsAbs and selecting the optimal bispecific molecule, amivantamab was generated and demonstrated superior antitumor activity in preclinical models. The unique mode of action of amivantamab may provide benefits to patients with malignancies associated with aberrant EGFR and MET signaling.

JOURNAL OF BIOLOGICAL CHEMISTRY (2021)

添加到收藏夹

Article Oncology

OA03.03 Datopotamab Deruxtecan (Dato-DXd; DS-1062), a TROP2 ADC, in Patients With Advanced NSCLC: Updated Results of TROPION-PanTumor01 Phase 1 Study

A. Spira et al.

Journal of Thoracic Oncology (2021)

添加到收藏夹

Article Oncology

P76.27 ORCHARD: A Biomarker-Directed Phase 2 Platform Study in pts with Advanced EGFRm NSCLC Progressing on First-Line Osimertinib

B.C. Cho et al.

Journal of Thoracic Oncology (2021)

添加到收藏夹

Article Oncology

Efficacy and Safety of Intrathecal Pemetrexed Combined With Dexamethasone for Treating Tyrosine Kinase Inhibitor-Failed Leptomeningeal Metastases From EGFR-Mutant NSCLC-a Prospective, Open-Label, Single-Arm Phase 1/2 Clinical Trial (Unique Identifier: ChiCTR1800016615)

Chengjuan Fan et al.

Summary: The study identified 50 mg pemetrexed as the recommended dose for treating EGFR-mutant non-small cell lung cancer leptomeningeal metastases, resulting in few adverse events and a good treatment response rate. IP was shown to be an effective treatment for patients who had failed tyrosine kinase inhibitors.

JOURNAL OF THORACIC ONCOLOGY (2021)

添加到收藏夹

Article Oncology

MET amplification identified by next-generation sequencing and its clinical relevance for MET inhibitors

Lun-Xi Peng et al.

Summary: MET amplification identified by FISH remains the optimal biomarker for predicting the efficacy of MET-TKI therapy in NSCLC patients, while the amplification identified by NGS does not show the same predictive ability, especially in distinguishing clinical outcomes. Further exploration is needed on the subtle differences in predicting efficacy by NGS.

EXPERIMENTAL HEMATOLOGY & ONCOLOGY (2021)

添加到收藏夹

Article Critical Care Medicine

Efficacy, safety, and genetic analysis of furmonertinib (AST2818) in patients with EGFR T790M mutated non-small-cell lung cancer: a phase 2b, multicentre

Yuankai Shi et al.

Summary: Furmonertinib demonstrates promising efficacy and acceptable safety profile in treating patients with EGFR T790M mutated NSCLC, serving as a new treatment option for the Chinese population after first or second generation EGFR TKIs.

LANCET RESPIRATORY MEDICINE (2021)

添加到收藏夹

Meeting Abstract Oncology

Amivantamab monotherapy and in combination with lazertinib in post-osimertinib EGFR-mutant NSCLC: Analysis from the CHRYSALIS study

N. B. Leighl et al.

ANNALS OF ONCOLOGY (2021)

添加到收藏夹

Meeting Abstract Oncology

A phase I/II, open-label study of BBT-176, a triple mutation targeting EGFR TKI, in patients with NSCLC who progressed after prior EGFR TKI therapy

S. M. Lim et al.

ANNALS OF ONCOLOGY (2021)

添加到收藏夹

Article Oncology

Bevacizumab plus erlotinib in Chinese patients with untreated, EGFR-mutated, advanced NSCLC (ARTEMIS-CTONG1509): A multicenter phase 3 study

Qing Zhou et al.

Summary: Dual inhibition of EGFR and VEGF pathways may delay therapeutic resistance in NSCLC, and a study on the efficacy and safety of erlotinib plus bevacizumab regimen in untreated patients showed significantly prolonged PFS, indicating potential benefits in advanced NSCLC treatment.

CANCER CELL (2021)

添加到收藏夹

Article Oncology

Biomarker-Directed Phase II Platform Study in Patients With EGFR Sensitizing Mutation-Positive Advanced/Metastatic Non-Small Cell Lung Cancer Whose Disease Has Progressed on First-Line Osimertinib Therapy (ORCHARD)

Helena A. Yu et al.

Summary: ORCHARD aims to characterize mechanisms of resistance to first-line osimertinib and explore treatments to overcome acquired resistance. The study's modular design allows for additional biomarker-directed cohorts and treatment options as understanding of osimertinib resistance mechanisms evolves.

CLINICAL LUNG CANCER (2021)

添加到收藏夹

Article Oncology

Datopotamab Deruxtecan, a Novel TROP2-directed Antibody-drug Conjugate, Demonstrates Potent Antitumor Activity by Efficient Drug Delivery to Tumor Cells

Daisuke Okajima et al.

Summary: The novel TROP2-directed antibody-drug conjugate (ADC), datopotamab deruxtecan, showed potent antitumor activity and acceptable safety profiles in preclinical models, suggesting it could be a valuable treatment option for patients with TROP2-expressing tumors.

MOLECULAR CANCER THERAPEUTICS (2021)

添加到收藏夹

Review Oncology

Overcoming therapy resistance in EGFR-mutant lung cancer

Antonio Passaro et al.

Summary: Tyrosine kinase inhibitors have greatly improved the clinical outcomes for non-small cell lung cancer patients with EGFR-activating mutations, but resistance eventually develops. Recent advances in detecting and overcoming EGFR TKI resistance mechanisms are discussed by Passaro and colleagues.

NATURE CANCER (2021)

添加到收藏夹

Article Medicine, General & Internal

Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC

S. S. Ramalingam et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

添加到收藏夹

Article Oncology

Osimertinib in Patients With Epidermal Growth Factor Receptor Mutation?Positive Non?Small-Cell Lung Cancer and Leptomeningeal Metastases: The BLOOM Study

James C. H. Yang et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

添加到收藏夹

Article Oncology

Osimertinib for Patients With Leptomeningeal Metastases Associated With EGFR T790M-Positive Advanced NSCLC: The AURA Leptomeningeal Metastases Analysis

Myung-Ju Ahn et al.

JOURNAL OF THORACIC ONCOLOGY (2020)

添加到收藏夹

Article Oncology

Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study

Lecia Sequist et al.

LANCET ONCOLOGY (2020)

添加到收藏夹

Article Critical Care Medicine

Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial

Yi-Long Wu et al.

LANCET RESPIRATORY MEDICINE (2020)

添加到收藏夹

Article Oncology

A phase II, multicenter, two cohort study of 160 mg osimertinib in EGFR T790M-positive non-small-cell lung cancer patients with brain metastases or leptomeningeal disease who progressed on prior EGFR TKI therapy

S. Park et al.

ANNALS OF ONCOLOGY (2020)

添加到收藏夹

Article Oncology

Pyrotinib in HER2-Mutant Advanced Lung Adenocarcinoma After Platinum-Based Chemotherapy: A Multicenter, Open-Label, Single-Arm, Phase II Study

Caicun Zhou et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

添加到收藏夹

Letter Oncology

Concurrent ERBB2 missense mutations D769Y and D742 N Are Novel Acquired Mechanism of Gefitinib Resistance but Responds to Gefitinib plus Pyrotinib

Yuling Zhou et al.

LUNG CANCER (2020)

添加到收藏夹

Review Oncology

MET-dependent solid tumours - molecular diagnosis and targeted therapy

Robin Guo et al.

NATURE REVIEWS CLINICAL ONCOLOGY (2020)

添加到收藏夹

Article Oncology

EGFR inhibition triggers an adaptive response by co-opting antiviral signaling pathways in lung cancer

Ke Gong et al.

NATURE CANCER (2020)

添加到收藏夹

Article Oncology

Capmatinib (INC280) Is Active Against Models of Non-Small Cell Lung Cancer and Other Cancer Types with Defined Mechanisms of MET Activation

Sabrina Baltschukat et al.

CLINICAL CANCER RESEARCH (2019)

添加到收藏夹

Article Oncology

Acquired BRAF Rearrangements Induce Secondary Resistance to EGFR therapy in EGFR-Mutated Lung Cancers

Morana Vojnic et al.

JOURNAL OF THORACIC ONCOLOGY (2019)

添加到收藏夹

Article Critical Care Medicine

Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial

Martin Reck et al.

LANCET RESPIRATORY MEDICINE (2019)

添加到收藏夹

Article Oncology

Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry

J. Mazieres et al.

ANNALS OF ONCOLOGY (2019)

添加到收藏夹

Article Medicine, General & Internal

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial

Tony S. K. Mok et al.

LANCET (2019)

添加到收藏夹

Article Oncology

Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial

Howard West et al.

LANCET ONCOLOGY (2019)

添加到收藏夹

Article Oncology

Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial

Haruhiro Saito et al.

LANCET ONCOLOGY (2019)

添加到收藏夹

Article Oncology

Cancer treatment and survivorship statistics, 2019

Kimberly D. Miller et al.

CA-A CANCER JOURNAL FOR CLINICIANS (2019)

添加到收藏夹

Article Oncology

MET IHC Is a Poor Screen for MET Amplification or MET Exon 14 Mutations in Lung Adenocarcinomas: Data from a Tri-Institutional Cohort of the Lung Cancer Mutation Consortium

Robin Guo et al.

JOURNAL OF THORACIC ONCOLOGY (2019)

添加到收藏夹

Article Multidisciplinary Sciences

EGFR and HER3 expression in circulating tumor cells and tumor tissue from non-small cell lung cancer patients

Heather Scharpenseel et al.

SCIENTIFIC REPORTS (2019)

添加到收藏夹

Review Oncology

Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer

Alessandro Leonetti et al.

BRITISH JOURNAL OF CANCER (2019)

添加到收藏夹

Article Oncology

Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial

Kazuhiko Nakagawa et al.

LANCET ONCOLOGY (2019)

添加到收藏夹

Review Oncology

Predictive markers of anti-VEGF and emerging role of angiogenesis inhibitors as immunotherapeutics

Priti S. Hegde et al.

SEMINARS IN CANCER BIOLOGY (2018)

添加到收藏夹

Review Oncology

Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors

D. Westover et al.

ANNALS OF ONCOLOGY (2018)

添加到收藏夹

Article Oncology

Ado-Trastuzumab Emtansine for Patients With HER2-Mutant Lung Cancers: Results From a Phase II Basket Trial

Bob T. Li et al.

JOURNAL OF CLINICAL ONCOLOGY (2018)

添加到收藏夹

Article Oncology

Improvement in Overall Survival in a Randomized Study That Compared Dacomitinib With Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations

Tony S. Mok et al.

JOURNAL OF CLINICAL ONCOLOGY (2018)

添加到收藏夹

Article Oncology

Consolidative Local Ablative Therapy Improves the Survival of Patients With Synchronous Oligometastatic NSCLC Harboring EGFR Activating Mutation Treated With First-Line EGFR-TKIs

Qinghua Xu et al.

JOURNAL OF THORACIC ONCOLOGY (2018)

添加到收藏夹

Article Medicine, General & Internal

Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer

J. -C. Soria et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

添加到收藏夹

Article Oncology

CNS Efficacy of Osimertinib in Patients With T790M-Positive Advanced Non-Small-Cell Lung Cancer: Data From a Randomized Phase III Trial (AURA3)

Yi-Long Wu et al.

JOURNAL OF CLINICAL ONCOLOGY (2018)

添加到收藏夹

Article Oncology

Phase Ib/II Study of Capmatinib (INC280) Plus Gefitinib After Failure of Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy in Patients With EGFR-Mutated, MET Factor-Dysregulated Non-Small-Cell Lung Cancer

Yi-Long Wu et al.

JOURNAL OF CLINICAL ONCOLOGY (2018)

添加到收藏夹

Article Oncology

LBA51Analysis of resistance mechanisms to osimertinib in patients with EGFR T790M advanced NSCLC from the AURA3 study

V A Papadimitrakopoulou et al.

ANNALS OF ONCOLOGY (2018)

添加到收藏夹

Article Oncology

LBA50Mechanisms of acquired resistance to first-line osimertinib: Preliminary data from the phase III FLAURA study

S S Ramalingam et al.

ANNALS OF ONCOLOGY (2018)

添加到收藏夹

Article Oncology

First-in-Human Phase I, Dose-Escalation and -Expansion Study of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, in Patients With Advanced Solid Tumors

John H. Strickler et al.

JOURNAL OF CLINICAL ONCOLOGY (2018)

添加到收藏夹

Article Oncology

ABBV-399, a c-Met Antibody-Drug Conjugate that Targets Both MET-Amplified and c-Met-Overexpressing Tumors, Irrespective of MET Pathway Dependence

Jieyi Wang et al.

CLINICAL CANCER RESEARCH (2017)

添加到收藏夹

Article Oncology

Gefitinib Plus Chemotherapy Versus Chemotherapy in Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer Resistant to First-Line Gefitinib (IMPRESS): Overall Survival and Biomarker Analyses

Tony S. K. Mok et al.

JOURNAL OF CLINICAL ONCOLOGY (2017)

添加到收藏夹

Article Oncology

Trastuzumab emtansine delays and overcomes resistance to the third-generation EGFR-TKI osimertinib in NSCLC EGFR mutated cell lines

Silvia La Monica et al.

JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2017)

添加到收藏夹

Article Oncology

Acquired BRAF V600E Mutation as Resistant Mechanism after Treatment with Third-Generation EGFR Tyrosine Kinase Inhibitor

Alessandra Bearz et al.

Journal of Thoracic Oncology (2017)

添加到收藏夹

Article Oncology

Lung Adenocarcinoma Harboring EGFR T790M and In Trans C797S Responds to Combination Therapy of First- and Third-Generation EGFR TKIs and Shifts Allelic Configuration at Resistance

Zhen Wang et al.

JOURNAL OF THORACIC ONCOLOGY (2017)

添加到收藏夹

Article Oncology

Combination Osimertinib and Gefitinib in C797S and T790M EGFR-Mutated Non-Small Cell Lung Cancer

Surein Arulananda et al.

JOURNAL OF THORACIC ONCOLOGY (2017)

添加到收藏夹

Article Oncology

Checkpoint Inhibitors in Metastatic EGFR-Mutated Non-Small Cell Lung Cancer A Meta-Analysis

Chee Khoon Lee et al.

JOURNAL OF THORACIC ONCOLOGY (2017)

添加到收藏夹

Article Oncology

Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial

Yi-Long Wu et al.

LANCET ONCOLOGY (2017)

添加到收藏夹

Article Critical Care Medicine

Activity and safety of AZD3759 in EGFR-mutant non-small-cell lung cancer with CNS metastases (BLOOM): a phase 1, open-label, dose-escalation and dose-expansion study

Myung-Ju Ahn et al.

LANCET RESPIRATORY MEDICINE (2017)

添加到收藏夹

Article Critical Care Medicine

Icotinib versus whole-brain irradiation in patients with EGFR-mutant non-small-cell lung cancer and multiple brain metastases (BRAIN): a multicentre, phase 3, open-label, parallel, randomised controlled trial

Jin-Ji Yang et al.

LANCET RESPIRATORY MEDICINE (2017)

添加到收藏夹

Article Oncology

First-line icotinib versus cisplatin/pemetrexed plus pemetrexed maintenance therapy for patients with advanced EGFR mutation-positive lung adenocarcinoma (CONVINCE): a phase 3, open-label, randomized study

Y. K. Shi et al.

ANNALS OF ONCOLOGY (2017)

添加到收藏夹

Article Oncology

Preclinical Evaluation of MET Inhibitor INC-280 With or Without the Epidermal Growth Factor Receptor Inhibitor Erlotinib in Non-Small-Cell Lung Cancer

Matthew S. Lara et al.

CLINICAL LUNG CANCER (2017)

添加到收藏夹

Article Oncology

Amplification of EGFR Wild-Type Alleles in Non-Small Cell Lung Cancer Cells Confers Acquired Resistance to Mutation-Selective EGFR Tyrosine Kinase Inhibitors

Shigenari Nukaga et al.

CANCER RESEARCH (2017)

添加到收藏夹

Article Oncology

Identifying the Appropriate FISH Criteria for Defining MET Copy Number-Driven Lung Adenocarcinoma through Oncogene Overlap Analysis

Sinead A. Noonan et al.

JOURNAL OF THORACIC ONCOLOGY (2016)

添加到收藏夹

Article Medicine, General & Internal

Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer

Martin Reck et al.

NEW ENGLAND JOURNAL OF MEDICINE (2016)

添加到收藏夹

Article Oncology

First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study

Y. -L. Wu et al.

ANNALS OF ONCOLOGY (2015)

添加到收藏夹

Meeting Abstract Oncology

Phase I studies of a selective cMet inhibitor AZD6094 (HMPL504/volitinib) in patients with advanced solid tumors

Ye Hua et al.

CANCER RESEARCH (2015)

添加到收藏夹

Meeting Abstract Oncology

Changing the paradigm for treating drug resistance in NSCLC: Novel combinations of AZD6094, a selective MET inhibitor, and an irreversible, selective (EGFRm/T790M) EGFRTKI, AZD9291

Celina D'Cruz et al.

CANCER RESEARCH (2015)

添加到收藏夹

Article Biochemistry & Molecular Biology

Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M

Kenneth S. Thress et al.

NATURE MEDICINE (2015)

添加到收藏夹

Article Oncology

Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial

Yi-Long Wu et al.

LANCET ONCOLOGY (2014)

添加到收藏夹

Article Oncology

EMD 1214063 and EMD 1204831 Constitute a New Class of Potent and Highly Selective c-Met Inhibitors

Friedhelm Bladt et al.

CLINICAL CANCER RESEARCH (2013)

添加到收藏夹

Article Oncology

Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations

Lecia V. Sequist et al.

JOURNAL OF CLINICAL ONCOLOGY (2013)

添加到收藏夹

Article Oncology

HER2 Amplification: A Potential Mechanism of Acquired Resistance to EGFR Inhibition in EGFR-Mutant Lung Cancers That Lack the Second-Site EGFRT790M Mutation

Ken Takezawa et al.

CANCER DISCOVERY (2012)

添加到收藏夹

Article Oncology

Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non-Small-Cell Lung Cancer in Asia (IPASS)

Masahiro Fukuoka et al.

JOURNAL OF CLINICAL ONCOLOGY (2011)

添加到收藏夹

Article Oncology

Incidence of EGFR Exon 19 Deletions and L858R in Tumor Specimens From Men and Cigarette Smokers With Lung Adenocarcinomas

Sandra P. D'Angelo et al.

JOURNAL OF CLINICAL ONCOLOGY (2011)

添加到收藏夹

Article Cell Biology

Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors

Lecia V. Sequist et al.

SCIENCE TRANSLATIONAL MEDICINE (2011)

添加到收藏夹

Article Medicine, General & Internal

Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer.

Rafael Rosell et al.

NEW ENGLAND JOURNAL OF MEDICINE (2009)

添加到收藏夹

Article Medicine, General & Internal

Gefitinib or Carboplatin-Paclitaxel in Pulmonary Adenocarcinoma.

Tony S. Mok et al.

NEW ENGLAND JOURNAL OF MEDICINE (2009)

添加到收藏夹

Article Oncology

Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers

H Shigematsu et al.

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2005)

添加到收藏夹

Article Medicine, General & Internal

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib

S Kobayashi et al.

NEW ENGLAND JOURNAL OF MEDICINE (2005)

添加到收藏夹

Article Multidisciplinary Sciences

Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways

R Sordella et al.

SCIENCE (2004)

添加到收藏夹

Article Medicine, General & Internal

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

TJ Lynch et al.

NEW ENGLAND JOURNAL OF MEDICINE (2004)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.